You are aware that achieving comparable results was the goal right? Did ppl already forget that non-inferiority was the only achievable result? All the analysts pumping company were aiming for non-inferiority results. By definition, that means it's comparable to Humalog.
The difference is that this is a P2 trial. With the data from this P2 trial, Co will design P3 trial to differentiate it apart from Humalog. This is one of the major purposes of P2, to help design a P3 that will get it past the FDA.
No matter how you slice today's results, it was a major success for company, validating their pipeline, and now BIOD has become a very solid long-term value play after this de-risking event.
All the bashers announcing defunct arguments about non-inf results being pointless are missing 2 things, non-inf drugs make up substantial size of different markets if differentiated w/ p3 data, and BIOD's mcap is pennies wrt to other comparable competitors. If you short tmw u are just hoping that today's banter from neutral (but rdy to buy on bounce from shakeout tmw if it happens) bashers manages to shake rookies out. That's a pretty weak hope for tomorrow, lmao.